1. Home
  2. SORA vs LUNG Comparison

SORA vs LUNG Comparison

Compare SORA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SORA

Top Win International Limited Ordinary Shares

N/A

Current Price

$2.79

Market Cap

69.4M

Sector

Industrials

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.20

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SORA
LUNG
Founded
2001
1995
Country
Hong Kong
United States
Employees
7
N/A
Industry
Other Specialty Stores
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.4M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SORA
LUNG
Price
$2.79
$1.20
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
12.0K
291.8K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$1.57
$1.13
52 Week High
$10.27
$5.46

Technical Indicators

Market Signals
Indicator
SORA
LUNG
Relative Strength Index (RSI) 74.93 35.75
Support Level $2.78 $1.13
Resistance Level $3.08 $1.64
Average True Range (ATR) 0.18 0.09
MACD 0.07 -0.01
Stochastic Oscillator 85.83 3.57

Price Performance

Historical Comparison
SORA
LUNG

About SORA Top Win International Limited Ordinary Shares

AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: